Pharmacy Freak Editorial Team

Introduction: The European Medicines Agency (EMA) is the central EU body that coordinates scientific evaluation, supervision and safety monitoring of human medicines. For B.Pharm students, understanding EMA functions and approvals is essential: committees like CHMP, PRAC, COMP and PDCO set scientific standards; systems such as the centralized procedure, conditional authorisation, orphan designation and PRIME accelerate … Read more

Understanding the organization structure of the US FDA and application types is essential for B.Pharm students focusing on regulatory affairs and drug development. This concise guide explains FDA centers (CDER, CBER, CDRH, CVM), key offices, regulatory pathways and common application types such as IND, NDA, ANDA, BLA, 505(b)(2), 510(k) and PMA. It also covers review … Read more

Overview of regulatory authorities in India (CDSCO) MCQs With Answer Understanding the Central Drugs Standard Control Organization (CDSCO) is essential for B. Pharm students preparing for careers in pharmaceuticals, regulatory affairs, and clinical research. This introduction explains CDSCO’s role under the Drugs and Cosmetics Act, core functions such as approval of new drugs, medical device … Read more

Post-approval changes to NDA or ANDA are modifications made to an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA) involving manufacturing, formulation, labeling, CMC, analytical methods, packaging, supplier or manufacturing site. Understanding regulatory pathways—such as prior-approval supplements (PAS), changes-being-effected (CBE), and annual reports—comparability protocols, SUPAC guidances, stability and bioequivalence requirements, and risk-based … Read more

The Abbreviated New Drug Application (ANDA) process is a core regulatory pathway for generic drug approval. This introduction explains key concepts B. Pharm students must know: ANDA submission under 505(j), bioequivalence (AUC/Cmax), Reference Listed Drug (RLD), FDA Orange Book, Paragraph IV patent challenges, 180-day exclusivity, BCS-based biowaivers, Drug Master Files (DMFs), cGMP, and labeling requirements. … Read more